drugset / Trial / NCT01922141

Aliskiren Study of Safety and Efficacy in Senior Hypertensives

NCT01922141

Phase 4 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension. It will also compare the long-term safety of an aliskiren-based regimen to a ramipril-based regimen

Timeline

Start
2015-05
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg
Comparator Ramipril Small molecule 5 mg
Comparator Ramipril Small molecule 10 mg
Background Hydrochlorothiazide Unknown 12.5 mg
Background Hydrochlorothiazide Unknown 25 mg

Indications